NEW YORK (GenomeWeb News) – Meridian Bioscience today said that sales grew 5 percent year over year during its fiscal third quarter as adoption of its molecular diagnostic products continued.

For the three months ended June 30, revenues rose to $42.1 million, up from $40.1, but below the Wall Street consensus of $46.5 million.

Net earnings for the quarter increased to $8.6 million, or $.21 per share, from $6.8 million, or $.17 per share, just shy of analyst estimates of $.22 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.